Donor reactions and injuries from whole blood donation.
B H Newman
https://pubmed.ncbi.nlm.nih.gov/9031492/Actively Recruiting
Led by University of Florida · Updated on 2025-11-06
220
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating how Alpha-1-antitrypsin AAT deficiency and Cystic Fibrosis CF, both genetic disorders, affect lung white blood cells called macrophages and their ability to respond to inflammation. AAT deficiency affects many people with chronic obstructive pulmonary disease COPD and may cause disease progression due to malfunctioning macrophages. CF causes lung tissue inflammation, and macrophages have a key role in both causing and resolving this inflammation. Participants are grouped into three categories those with AAT deficiency, those with CF carrying the Delta F508 mutation, and those without lung disease. At each study visit, all participants undergo a history and physical exam, blood draws, and lung function tests involving forceful breathing before and after using an Albuterol inhaler. The inhaler is used as part of the pulmonary function testing with at least a 30-minute wait between inhaler use and the second lung test. During the study, researchers evaluate lung macrophage function, blood levels of alpha-1 antitrypsin and an inflammatory marker called C-reactive protein, and lung function. These assessments are done on average within 30 days after sample collection or testing. Participants medical history, physical exams, and lung testing are repeated at each visit to monitor changes and understand how these diseases impact lung immune response and inflammation.
CONDITIONS
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
A
Allison E. Faunce, B.A.
M
Michelle Owens, RN, BSN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Florida
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Ongoing throughout the study duration
Participants attend study visits where their medical history is reviewed and a physical exam is conducted. Blood is drawn for testing and lung function is assessed through pulmonary function tests before and after using an Albuterol inhaler.
Repeated visits as scheduled by the study team
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
B H Newman
https://pubmed.ncbi.nlm.nih.gov/9031492/Tunda Hidvegi, Bela Z Schmidt, Pamela Hale...
https://pubmed.ncbi.nlm.nih.gov/16183649/David H Perlmutter
https://pubmed.ncbi.nlm.nih.gov/12464659/J Seager Danciger, M Lutz, S Hama...
https://pubmed.ncbi.nlm.nih.gov/15183091/C A Blank, M Brantly
https://pubmed.ncbi.nlm.nih.gov/8109800/Randal J Kaufman
https://pubmed.ncbi.nlm.nih.gov/12438434/D A Lomas, D L Evans, J T Finch...
https://pubmed.ncbi.nlm.nih.gov/1608473/Yukako Oda, Tetsuya Okada, Hiderou Yoshida...
https://pubmed.ncbi.nlm.nih.gov/16449189/A Yoshida, J Lieberman, L Gaidulis...
https://pubmed.ncbi.nlm.nih.gov/1083527/J O Jeppsson
https://pubmed.ncbi.nlm.nih.gov/1084290/University of Florida
Lead Sponsor